Home / Intelligence / Case Studies / Cross-Functional Launch Strategy Alignment Workshop
Trinity organized a full day on-site workshop to bring together key cross functional client teams to align on a final launch strategy for their mNSCLC asset in Japan.
Geographic Scope: 
Client Situation:
The client wanted to build alignment on the launch pricing & market access assumptions for their asset in metastatic non-small cell lung cancer (mNSCLC) and metastatic colorectal cancer (mCRC) in Japan, including consideration of all forecasting assumptions and pricing and market access (P&MA) risks.
Trinity’s Solution:
Trinity conducted targeted secondary research to determine the existing mNSCLC and mCRC treatment paradigm, as well as oncology regulatory landscape in Japan.
Trinity then organized a full-day day workshop at the client’s local office in Japan to enable cross functional client teams to collaborate on forecasting assumptions and optimal launch strategies.
Deliverables
- Case studies of oncology analogues and recent pricing outcomes in JPN
- In-depth policy review of JPN’s new health technology assessment (HTA) process
- Final report with detailed summary of workshop outputs
- Final launch pricing and commercial strategy
Project Outcomes & Impact:
The workshop generated the opportunity for the client’s local team to deliver nuanced local expertise and strategic insights to the global team to ensure that the updated launch forecast model included realistic access assumptions.
Related Intelligence
Webinars
Trinity Annual Drug Index
April 3, 2025 | 12:00 – 12:45 PM ET
White Paper & Webinar: This report, the seventh in our Trinity Drug Index series, outlines key themes and emerging trends in the industry as we progress towards a new world of targeted and innovative products. We provide a comprehensive evaluation of the performance of novel drugs approved by the FDA in 2021, scoring each on […]
Sign Up Now
Blog
5 Key Trends in Global Market Access
Key impacts on the market access and payer environment are beginning to unfold from policies enacted in 2023 and new policies enacted in 2024. To gather insights into the latest trends, Trinity Life Sciences conducted interviews with key stakeholders across various pricing and market access landscapes. Trinity is closely monitoring the evolving global advanced therapeutics […]
Read More
White Papers
Moving the Needle: Lessons from the 2023 Launch Class
The 2023 launch class exceeded Trinity Life Sciences’ expectations with only 50% underperforming their pre-launch first year forecasts while 39% overperformed, indicating an improvement from prior years (54% and 35%, respectively, for 2020–2023). This was driven by notable improvements in “Specialty and Large Market” products (36% overperformed vs. 18% average in years prior) and First Launch Companies (33% overperformed vs. 20% in years prior). The needle is moving.
Read More